ArticleTranslational vision science & technology2026
Choroidal Vascular Remodeling After Loading Injections of Faricimab in Diabetic Macular Edema.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Purpose: We evaluated choroidal structural changes in patients with diabetic macular edema (DME) after a loading phase of 3 monthly intravitreal faricimab injections. Methods: This retrospective cohort study included treatment-naïve patients with newly diagnosed DME who received 3 monthly intravitreal injections of faricimab. Researchers analyzed data from patients with available follow-up at 1 month after the third injection. Assessments included best-corrected visual acuity, central retinal thickness (CRT), and subfoveal choroidal thickness (SFCT). Hyper-reflective choroidal foci, and the choroidal vascularity index (CVI) of Sattler's and Haller's layers were assessed using enhanced depth imaging optical coherence tomography within a 1.5-mm zone. Results: A total of 24 eyes from 24 treatment-naïve patients were included. After the loading phase, best-corrected visual acuity improved significantly, and both CRT and SFCT decreased markedly. The number of hyper-reflective choroidal foci remained unchanged, and the CVI of Haller's layer increased significantly. No ocular or systemic adverse events occurred during the study period. Conclusions: Loading-phase treatment with faricimab produced functional and anatomical improvements in the retina and choroid of patients with DME. These findings suggest that faricimab may contribute to choroidal vascular remodeling in addition to resolving retinal fluid. Translational Relevance: This study shows that observed associations in imaging biomarkers after faricimab loading, such as SFCT and CVI, may provide additional clinical insights for individualized patient assessment in real-world settings, supporting the use of choroidal imaging as a complementary tool for managing diabetic macular edema.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.